三博脑科(301293) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for the current period is ¥336,930,401.64, representing a 7.89% increase compared to ¥312,006,313.10 in the same period last year[18]. - The net profit attributable to shareholders for the current period is ¥33,444,602.02, a 35.29% increase from ¥24,785,199.73 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 32.23% to ¥32,333,153.81 from ¥24,452,469.87[26]. - The net cash flow from operating activities decreased by 51.67% to ¥28,472,761.60 compared to ¥58,530,558.21 in the same period last year[18]. - The total operating revenue for the first quarter of 2024 was CNY 336,930,401.64, an increase of 7.4% compared to CNY 312,294,864.53 in the previous period[45]. - The net profit for the first quarter of 2024 reached CNY 38,749,465.53, compared to CNY 28,314,295.71 in the same period last year, marking a significant increase of 36.5%[45]. - The profit attributable to the parent company's shareholders was CNY 33,444,602.02, up from CNY 24,720,632.41, representing a growth of 35.2%[45]. - The total comprehensive income attributable to the parent company was CNY 33,444,602.02, an increase from CNY 24,720,632.41 in the previous period, representing a growth of approximately 35%[52]. - The company’s total comprehensive income increased to CNY 38,749,465.53 from CNY 28,314,295.71, representing a growth of about 37%[52]. Assets and Liabilities - The total assets at the end of the reporting period are ¥3,091,516,574.64, a decrease of 1.36% from ¥3,134,086,644.39 at the end of the previous year[18]. - The equity attributable to shareholders at the end of the reporting period is ¥2,360,928,183.30, reflecting a 1.56% increase from ¥2,324,694,267.96 at the end of the previous year[18]. - The company's total liabilities decreased from ¥442,427,851.99 to ¥348,528,885.92, a reduction of approximately 21.2%[35]. - The total liabilities decreased to CNY 539,140,424.82 from CNY 625,949,273.42, indicating a reduction of approximately 13.9%[45]. - Non-current assets increased to ¥1,421,203,863.40 from ¥1,400,473,604.42, reflecting a growth of about 1.5%[35]. - The company's long-term deferred expenses increased from ¥87,427,133.37 to ¥91,098,789.12, an increase of about 4.6%[35]. - The company's accounts payable decreased significantly from ¥252,581,968.11 to ¥209,978,961.69, a reduction of approximately 16.9%[35]. - The company reported a significant increase in other current assets from ¥14,729,242.10 to ¥27,842,088.25, a growth of about 89.5%[35]. Cash Flow - Cash inflows from operating activities totaled CNY 375,826,914.79, compared to CNY 310,010,137.24 in the prior period, reflecting an increase of about 21%[53]. - Cash received from investment recoveries was CNY 972,000,000.00, significantly higher than CNY 160,000,000.00 in the previous period, marking an increase of over 508%[53]. - Total cash outflows from operating activities were CNY 347,354,153.19, up from CNY 251,097,980.32, which is an increase of around 38%[53]. - The cash flow from investment activities generated a net inflow of CNY 304,411,613.61, a turnaround from a net outflow of CNY -40,860,371.71 in the previous period[51]. - The cash and cash equivalents at the end of the period amounted to CNY 1,146,809,266.74, up from CNY 610,230,172.95, showing an increase of 88.5%[51]. - As of March 31, 2024, the company's cash and cash equivalents increased to ¥1,146,809,271.83 from ¥822,122,353.04, representing a growth of approximately 39.5%[34]. Acquisitions and Investments - The company recorded a gain of CNY 1,580,880.66 from the acquisition of Chongqing Xida Pharmaceutical Co., Ltd.[16]. - The increase in net profit is attributed to the contributions from the acquisitions of Beijing Huibokang Medical Equipment Co., Ltd. and Luoyang Wuyi 113 Neurosurgery Hospital Co., Ltd. in September and October 2023, respectively[26]. - The company acquired Chongqing Xida and Chongqing Jialele Medical Equipment Co., Ltd. in January 2024, which also contributed to the increase in net profit[26]. - The company completed the acquisition of 100% equity in Chongqing Xida Pharmaceutical Co., Ltd. for ¥17,767,700, enhancing its procurement system and industry chain layout[36]. - The company aims to optimize its business structure through strategic acquisitions, aligning with its long-term development goals[36]. Non-Operating Items - The company reported a non-operating loss of CNY 253,670.88 from the disposal of non-current assets in the first quarter[14]. - Government subsidies recognized in the current period amounted to CNY 1,046,854.72, contributing positively to the financial results[14]. - The fair value changes from financial assets and liabilities held by non-financial enterprises generated a profit of CNY 2,535,514.30, primarily from structured deposits[14]. - Other non-operating expenses totaled CNY -3,792,506.29, mainly due to fines, donations, and medical dispute compensations[16]. - The total impact of non-recurring gains and losses after tax was CNY 1,111,448.21[16]. Shareholder Information - The company has a total of 122,453,493 shares, with 33,685,118 shares subject to lock-up until May 5, 2024[9]. - The company has no plans for retrospective adjustments or restatements of previous accounting data[13]. - The first quarter report has not been audited[3]. - The company ensures the accuracy and completeness of the financial information disclosed in the quarterly report[2]. - Basic and diluted earnings per share remained at CNY 0.21, consistent with the previous period[52]. - The weighted average return on equity decreased to 1.43% from 2.04% in the previous year[18].